Effects of MAO-B inhibitors on non-motor symptoms and quality of life in Parkinson’s disease: A systematic review

Non-motor symptoms (NMS) are common among patients with Parkinson’s disease and reduce patients’ quality of life (QOL). However, there remain considerable unmet needs for NMS management. Three monoamine oxidase B inhibitors (MAO-BIs), selegiline, rasagiline, and safinamide, have become commercially...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsuboi, Takashi, Satake, Yuki, Hiraga, Keita, Yokoi, Katsunori, Hattori, Makoto, Suzuki, Masashi, Hara, Kazuhiro, Ramirez-Zamora, Adolfo, Okun, Michael S., Katsuno, Masahisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9192747/
https://www.ncbi.nlm.nih.gov/pubmed/35697709
http://dx.doi.org/10.1038/s41531-022-00339-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9192747/
https://www.ncbi.nlm.nih.gov/pubmed/35697709
http://dx.doi.org/10.1038/s41531-022-00339-2

Ejemplares similares